In Vitro Antimicrobial Activity of Fibrin Sealants Containing Antimicrobial Agents

被引:8
作者
Nakaminami, Hidemasa [1 ]
Suzuki, Yosuke [1 ]
Suzuki, Rina [1 ]
Saito, Aya [2 ]
Motomura, Noboru [2 ]
Noguchi, Norihisa [1 ]
机构
[1] Tokyo Univ Pharm & Life Sci, Sch Pharm, Dept Microbiol, Hachioji, Tokyo 1920392, Japan
[2] Univ Tokyo, Dept Cardiothorac Surg, Bunkyo Ku, Tokyo, Japan
关键词
SURGICAL SITE INFECTIONS; GLUE; VANCOMYCIN;
D O I
10.1089/sur.2012.224
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Background: Antimicrobial prophylaxis is required to prevent surgical site infections (SSIs). However, it is difficult to maintain prolonged antimicrobial activity in the surgical incision. Fibrin sealants are used primarily for hemostasis, suture support, or the adhesion of tissues. The aim of this study was to develop fibrin sealants that exhibit antimicrobial activity due to the addition of an antimicrobial agent. Methods: We determined the potencies and activities of cefazolin, ampicillin-sulbactam, vancomycin, teicoplanin, and arbekacin eluted from fibrin sealants. The antimicrobial activity was evaluated using methicillin-resistant Staphylococcus aureus (MRSA), multi-drug-resistant Pseudomonas aeruginosa (MDRP), and multi-drug-resistant Acinetobacter baumannii (MDRAB), which are the major pathogens responsible for hospital-acquired infections. Results: Each antimicrobial agent eluted continuously from the fibrin clots for approximately two weeks. All eluates from fibrin clots containing antimicrobial agents maintained antimicrobial activity against MRSA for at least 7d. The eluates from fibrin clots containing ampicillin-sulbactam inhibited the growth of both MDRP and MDRAB for at least 5d. Conclusion: Our data suggest that the addition of an antimicrobial agent to fibrin sealants is a useful method to prevent SSIs caused by bacteria, including antimicrobial-resistant strains.
引用
收藏
页码:29 / 35
页数:7
相关论文
共 22 条
  • [1] Anderson DJ, 2008, INFECT CONT HOSP EP, V29, pS51, DOI [10.1086/676022, 10.1017/S0899823X00193869]
  • [2] Clinical and Laboratory Standards Institute, 2009, M7A8 CLIN LAB STAND
  • [3] PROTEIN-BINDING AND SERUM BACTERICIDAL ACTIVITIES OF VANCOMYCIN AND TEICOPLANIN
    DYKHUIZEN, RS
    HARVEY, G
    STEPHENSON, N
    NATHWANI, D
    GOULD, IM
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (08) : 1842 - 1847
  • [4] PHARMACOKINETICS OF SULTAMICILLIN IN MICE, RATS, AND DOGS
    ENGLISH, AR
    GIRARD, D
    HASKELL, SL
    [J]. ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1984, 25 (05) : 599 - 602
  • [5] Fujimoto K, 1997, J BIOMED MATER RES, V36, P564, DOI 10.1002/(SICI)1097-4636(19970915)36:4<564::AID-JBM16>3.0.CO
  • [6] 2-A
  • [7] Topical haemostatic agents for skin wounds: a systematic review
    Groenewold, Marieke D.
    Gribnau, Astrid J.
    Ubbink, Dirk T.
    [J]. BMC SURGERY, 2011, 11
  • [8] Fate of fibrin sealant in pericardial space
    Hattori, R
    Otani, H
    Omiya, H
    Tabata, S
    Nakao, Y
    Yamamura, T
    Osako, M
    Saito, Y
    Imamura, H
    [J]. ANNALS OF THORACIC SURGERY, 2000, 70 (06) : 2132 - 2136
  • [9] Microbiologic Characteristics and In Vitro Susceptibility to Antimicrobials in a Large Population of Patients with Cardiovascular Implantable Electronic Device Infection
    Jan, Emilie
    Camou, Fabrice
    Texier-Maugein, Jeannette
    Whinnett, Zachary
    Caubet, Olivier
    Ploux, Sylvain
    Pellegrin, Jean-Luc
    Ritter, Philippe
    Metayer, Philippe L.
    Roudaut, Raymond
    Haissaguerre, Michel
    Bordachar, Pierre
    [J]. JOURNAL OF CARDIOVASCULAR ELECTROPHYSIOLOGY, 2012, 23 (04) : 375 - 381
  • [10] Surgical site infections: incidence and trends at a community teaching hospital
    Kassavin, Daniel S.
    Pascarella, Linda
    Goldfarb, Michael A.
    [J]. AMERICAN JOURNAL OF SURGERY, 2011, 201 (06) : 749 - 753